Drug Discovery

Moderna doses first patient with its IL-2 mRNA therapeutic candidate

2 August 2021

Moderna has dosed the first patients in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2, modified for the expansion of regulatory T cells. mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic and its first subcutaneously administered therapeutic program. “The initiation of the Phase I study of mRNA-6231 is an important milestone […]

ACRO releases toolkit to help advance decentralised clinical trials

2 August 2021

The Association of Clinical Research Organizations (ACRO) released its DCT Toolkit, which lays out a vision for how decentralised clinical trials (DCTs) can be planned and executed now and in the future. When Covid-19 hit in March 2020, clinical trial participants were cut off from in-person clinical research visits. CROs and technology companies were often […]

Sitting down with… Jerome Guillemont, NovAliX

2 August 2021

Lu Rahman speaks to Dr Jerome Guillemont, Head of Drug Discovery at NovAliX, a drug discovery contract research organisaton. Guillemont brings a wealth of experience in drug discovery to this role, having spent more than thirty years in pharmaceutical companies, working on numerous drug candidates. He is in charge of leading new research projects with […]

What has 2020 taught us about lab automation?

30 July 2021

Dr Patrick Courtney (SiLA consortium), Burkhard Schaefer (SiLA consortium/ASTM AnIML) and Oliver Peter, Senior Director, Senior Group Leader Biology Technologies and Lead Discovery, Biology, Idorsia Pharmaceuticals, look at the importance of automation in the face of global disease. As we write this, vaccines are being injected into arms at scale and pace in many countries […]

Gene therapy enables new treatments for neurodegenerative diseases

29 July 2021

The University of Sheffield and the Cell and Gene Therapy Catapult have launched a gene therapy programme which could pave the way for novel treatments for neurodegenerative diseases. The research has been awarded £513,141 from LifeArc and the Motor Neurone Disease Association to test the feasibility and efficiency of a gene therapy programme to treat […]

New data supports targeting Trk receptors for treating Alzheimer’s

29 July 2021

AlzeCure Pharma’s presentation and poster regarding the clinical candidate drug ACD856 for Alzheimer’s disease, presented at the Alzheimer’s Association International Conference (AAIC) 2021 on July 26-30 in Denver, USA, are now available on its website. The abstract, ACD856 – a novel positive allosteric modulator of Trk-signaling in clinical development for the treatment of Alzheimer’s disease, […]

The CELL CULTURE innovations increasing drug discovery success

8 August 2020 , By Helen Stewart-Miller and Abby George , Volume 21 Issue 3 - Summer 2020

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet, despite the drive to fail […]

Antimicrobial resistance threatens to undermine our healthcare system

15 April 2020 , By Dr Peter Jackson , Volume 21 Issue 2 - Spring 2020

Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 – Spring 2020 The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored. While antimicrobial resistance (AMR) does not present the imminent ‘tsunami’ […]

How sharing compound solubility data can advance drug discovery

9 April 2020 , By Andrii Lozoniuk , Volume 21 Issue 2 - Spring 2020

By Andrii Lozoniuk Volume 21 Issue 2 – Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can help pharmaceutical companies minimise unnecessary expenditures in terms of […]

Target discovery and drug development what comes after CRISPR?

6 April 2020 , By Benedict CS Cross , Volume 21 Issue 2 - Spring 2020

Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 – Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have seen an abundance of new tools and […]

Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free